The synergistic therapy combining Cu2-xSe/ZIF-8 nanoparticles with crizotinib for the treatment of colorectal cancer

Read full text Summarise with VIRAT
Authors: Long Xu, Mingming Zhang, Zheng Peng, Mengni Zhu, Qin Ma, Yun Qian, Gongli Yang, Xiaoli Zheng, Zhenyu Liu, Yu Meng, Zhili Zhang, Yao Peng
+1 more Yong Zhang
Cited by: 0
References: 48

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Colorectal cancer (CRC) is the second leading cause of cancer-related mortality worldwide, yet chemotherapy resistance, tumor recurrence, and systemic toxicity limit current therapies. Here, we developed a multimodal Cu 2-x Se@ZIF-8-crizotinib (CSZC) nanoplatform that integrates chemosensitization, photodynamic therapy (PDT), and self-sustaining chemodynamic therapy (CDT). The core–shell structure, consisting of ultrafine Cu 2-x Se nanocrystals confined within a ZIF-8 framework, enables efficient crizotinib loading through mesoporous confinement and π-π interactions. Under near-infrared (808 nm) irradiation, photocatalysis converts O 2 into cytotoxic singlet oxygen ( 1 O 2 ), inducing mitochondrial dysfunction and DNA damage. Meanwhile, the acidic tumor microenvironment triggers ZIF-8 degradation, promoting Cu + /Cu 2+ -mediated Fenton-like conversion of H 2 O 2 into hydroxyl radicals (·OH). Concurrently, released crizotinib inhibits ALK/ROS1 signaling and enhances ROS-induced endoplasmic reticulum stress, forming a drug-sensitization/ROS-amplification feedback loop. This PDT-CDT-chemotherapy synergistic strategy provides an effective approach to enhance chemosensitivity and antitumor efficacy in CRC.

Fields of Study & Subjects

Nanoplatforms for cancer theranostics Photodynamic Therapy Research Studies Advanced Nanomaterials in Catalysis

Publication details

Journal / source
Colloids and Interface Science Communications
Volume
72
Pages
100890–100890
Publication date
26 March 2026
Language
EN